Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer

被引：16

作者：

Vincenzi, Bruno ^{[1
]}

Schiavon, Gaia ^{[1
]}

Pantano, Francesco ^{[1
]}

Santini, Daniele ^{[1
]}

Tonini, Giuseppe ^{[1
]}

机构：

[1] Campus Biomed Univ, Div Med Oncol, I-00128 Rome, Italy

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 08期

关键词：

fluorouracil; colorectal cancer; irinotecan; predictive; toxic effects;

D O I：

10.1038/ncponc1137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer represents a major health problem in the Western world. Many drugs have been used for the treatment of this disease, but there is little information about how predictive factors can be used to aid treatment response and anticipate toxic effects related to anticancer treatment in colorectal cancer. In this Review we analyze the main data about this field of investigation, and highlight the most important predictive factors that relate to the toxic effects experienced by colorectal cancer patients treated with anticancer chemotherapy, both in the adjuvant and in the advanced settings. The predictive factors are grouped on the basis of the different anticancer drugs. We discuss the rationale for tailoring anticancer treatment in patients with colorectal cancer according to individual molecular and clinical features, with the aim of improving response rates and reducing the incidence of toxic events.

引用

页码：455 / 465

页数：11

共 106 条

[1] The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons [J].

Adelsberger, H ;

Quasthoff, S ;

Grosskreutz, J ;

Lepier, A ;

Eckel, F ;

Lersch, C .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) :25-32

[2]

Allain P, 2000, DRUG METAB DISPOS, V28, P1379

[3] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[4] Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients:: Final results of GERCOR c96.1 [J].

Andre, Thierry ;

Quinaux, Emmanuel ;

Louvet, Christophe ;

Colin, Philippe ;

Gamelin, Erik ;

Bouche, Olivier ;

Achille, Emmanuel ;

Piedbois, Pascal ;

Tubiana-Mathieu, Nicole ;

Boutan-Laroze, Arnaud ;

Flesch, Michel ;

Lledo, Gerard ;

Raoul, Yves ;

Debrix, Isabelle ;

Buyse, Marc ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3732-3738

[5] RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD-PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11 [J].

ARAKI, E ;

ISHIKAWA, M ;

IIGO, M ;

KOIDE, T ;

ITABASHI, M ;

HOSHI, A .

JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (06) :697-702

[6] A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells [J].

Bagley, PJ ;

Selhub, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :13217-13220

[7] Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism? [J].

Beutler, E ;

Gelbart, T ;

Demina, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8170-8174

[8] Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer [J].

Blanke, CD ;

Kasimis, B ;

Schein, P ;

Capizzi, R ;

Kurman, M .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :915-920

[9]

Boige V, 1998, B CANCER, P26

[10]

BRIENZA S, 1995, P AM SOC CLIN ONC AN

← 1 2 3 4 5 6 7 8 9 10 →